Discovery of positive allosteric modulators and silent allosteric modulators of the μ-opioid receptor

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 26, 2013, Pages 10830-10835

  Burford, Neil T ^a   Clark, Mary J ^b   Wehrman, Tom S ^c   Gerritz, Samuel W ^a   Banks, Martyn ^a   O'Connell, Jonathan ^a   Traynor, John R ^b   Alt, Andrew ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c DiscoveRx Corporation   (United States)

Author keywords

Analgesia; DAMGO; Endomorphin; Endorphins; Enkephalins

Indexed keywords

BETA ARRESTIN; BMS 986121; BMS 986122; MU OPIATE RECEPTOR; MU OPIATE RECEPTOR AGONIST; UNCLASSIFIED DRUG;

ALLOSTERISM; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; HIGH THROUGHPUT SCREENING; MOUSE; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

ANALGESIA; DAMGO; ENDOMORPHIN; ENDORPHINS; ENKEPHALINS;

ALLOSTERIC REGULATION; ALLOSTERIC SITE; ANIMALS; ARRESTINS; CELL LINE; CHO CELLS; CRICETINAE; CRICETULUS; DRUG DISCOVERY; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; LIGANDS; RATS; RECEPTORS, OPIOID, MU; SULFONES; THIAZOLES;

EID: 84879514548     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1300393110     Document Type: Article

References (34)

1. Jacoby E, Bouhelal R, Gerspacher M, Seuwen K (2006) The 7 TM G-protein-coupled receptor target family. ChemMedChem 1(8):761-782.
2. Waldhoer M, Bartlett SE, Whistler JL (2004) Opioid receptors. Annu Rev Biochem 73: 953-990.
3. Whalen EJ, Rajagopal S, Lefkowitz RJ (2011) Therapeutic potential of β-arrestin- and G protein-biased agonists. Trends Mol Med 17(3):126-139.
4. Shukla AK, Xiao K, Lefkowitz RJ (2011) Emerging paradigms of β-arrestin-dependent seven transmembrane receptor signaling. Trends Biochem Sci 36(9):457-469.
5. Matthes HW, et al. (1996) Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene. Nature 383(6603):819-823.
6. Manglik A, et al. (2012) Crystal structure of the μ-opioid receptor bound to a morphinan antagonist. Nature 485(7398):321-326.
7. Dietis N, et al. (2009) Simultaneous targeting of multiple opioid receptors: A strategy to improve side-effect profile. Br J Anaesth 103(1):38-49.
8. Davis MP (2012) Evidence from basic research for opioid combinations. Expert Opin Drug Discov 7(2):165-178.
9. Burford NT, Watson J, Bertekap R, Alt A (2011) Strategies for the identification of allosteric modulators of G-protein-coupled receptors. Biochem Pharmacol 81(6): 691-702.
10. Birdsall NJ, Lazareno S (2005) Allosterism at muscarinic receptors: Ligands and mechanisms. Mini Rev Med Chem 5(6):523-543.
11. Bruns RF, Fergus JH (1990) Allosteric enhancement of adenosine A1 receptor binding and function by 2-amino-3-benzoylthiophenes. Mol Pharmacol 38(6):939-949.
12. Conn PJ, Jones CK, Lindsley CW (2009) Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders. Trends Pharmacol Sci 30(3): 148-155.
13. Gao ZG, Kim SK, Ijzerman AP, Jacobson KA (2005) Allosteric modulation of the adenosine family of receptors. Mini Rev Med Chem 5(6):545-553.
14. Gasparini F, Kuhn R, Pin JP (2002) Allosteric modulators of group I metabotropic glutamate receptors: Novel subtype-selective ligands and therapeutic perspectives. Curr Opin Pharmacol 2(1):43-49.
15. Bassoni DL, Raab WJ, Achacoso PL, Loh CY, Wehrman TS (2012) Measurements of β-arrestin recruitment to activated seven transmembrane receptors using enzyme complementation. Methods Mol Biol 897:181-203.
16. Clark MJ, Furman CA, Gilson TD, Traynor JR (2006) Comparison of the relative efficacy and potency of mu-opioid agonists to activate Galpha(i/o) proteins containing a pertussis toxin-insensitive mutation. J Pharmacol Exp Ther 317(2):858-864.
17. Noetzel MJ, et al. (2012) Functional impact of allosteric agonist activity of selective positive allosteric modulators of metabotropic glutamate receptor subtype 5 in regulating central nervous system function. Mol Pharmacol 81(2):120-133.
18. Alt A, et al. (1998) Stimulation of guanosine-5'-O-(3-[35S]thio) triphosphate binding by endogenous opioids acting at a cloned mu receptor. J Pharmacol Exp Ther 286(1): 282-288.
19. Liu W, et al. (2012) Structural basis for allosteric regulation of GPCRs by sodium ions. Science 337(6091):232-236.
20. Werling LL, Puttfarcken PS, Cox BM (1988) Multiple agonist-affinity states of opioid receptors: Regulation of binding by guanyl nucleotides in guinea pig cortical, NG108-15, and 7315c cell membranes. Mol Pharmacol 33(4):423-431.
21. Sharma S, Rodriguez AL, Conn PJ, Lindsley CW (2008) Synthesis and SAR of a mGluR5 allosteric partial antagonist lead: Unexpected modulation of pharmacology with slight structural modifications to a 5-(phenylethynyl) pyrimidine scaffold. Bioorg Med Chem Lett 18(14):4098-4101.
22. Koole C, et al. (2010) Allosteric ligands of the glucagon-like peptide 1 receptor (GLP- 1R) differentially modulate endogenous and exogenous peptide responses in a pathway-selective manner: Implications for drug screening. Mol Pharmacol 78(3): 456-465.
23. McNicol E, et al.; Americal Pain Society (2003) Management of opioid side effects in cancer-related and chronic noncancer pain: A systematic review. J Pain 4(5):231-256.
24. Roques BP, Fournié-Zaluski MC, Wurm M (2012) Inhibiting the breakdown of endogenous opioids and cannabinoids to alleviate pain. Nat Rev Drug Discov 11(4):292-310.
25. Levine JD, Gordon NC, Jones RT, Fields HL (1978) The narcotic antagonist naloxone enhances clinical pain. Nature 272(5656):826-827.
26. Gjoni T, Urwyler S (2008) Receptor activation involving positive allosteric modulation, unlike full agonism, does not result in GABAB receptor desensitization. Neuropharmacology 55(8):1293-1299.
27. DeWire SM, et al. (2013) A G protein-biased ligand at the μ-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine. J Pharmacol Exp Ther 344(3):708-717.
28. Davis CN, et al. (2009) Differential regulation of muscarinic M1 receptors by orthosteric and allosteric ligands. BMC Pharmacol 9:14.
29. Emmerson PJ, et al. (1996) Characterization of opioid agonist efficacy in a C6 glioma cell line expressing the mu opioid receptor. J Pharmacol Exp Ther 278(3):1121-1127.
30. Clark MJ, Harrison C, Zhong H, Neubig RR, Traynor JR (2003) Endogenous RGS protein action modulates mu-opioid signaling through Galphao. Effects on adenylyl cyclase, extracellular signal-regulated kinases, and intracellular calcium pathways. J Biol Chem 278(11):9418-9425.
31. Lester PA, Traynor JR (2006) Comparison of the in vitro efficacy of mu, delta, kappa and ORL1 receptor agonists and non-selective opioid agonists in dog brain membranes. Brain Res 1073-1074:290-296.
32. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254.
33. Neilan CL, Akil H, Woods JH, Traynor JR (1999) Constitutive activity of the delta-opioid receptor expressed in C6 glioma cells: Identification of non-peptide delta-inverse agonists. Br J Pharmacol 128(3):556-562.
34. Lee KO, Akil H, Woods JH, Traynor JR (1999) Differential binding properties of oripavines at cloned mu- and delta-opioid receptors. Eur J Pharmacol 378(3):323-330.